Nonalcoholic fatty liver disease in severely obese individuals: The influence of bariatric surgery

Andrade, Antônio Ricardo de; Cotrim, Helma Pinchemel; Alves, Erivaldo; Soares, Daniela Arruda; Rocha, Raquel; Almeida, Alessandro de Moura; Almeida, Carolina Gomes da Silva Tolentino Gonçalves de; Freitas, Luiz Antônio de

doi:10.1016/s1665-2681(19)31838-1

Cited by 24 publications

(7 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More recently, BS has become an accepted therapeutic option for MO patients and has been associated with histological improvement of NAFLD [ 7 , 8 , 9 , 10 ]. When liver biopsies performed before and after the weight loss caused by the surgery were compared, it was shown that this treatment determines an improvement or stabilization of SS, NASH and fibrosis [ 9 , 10 ].…”

Section: Discussionmentioning

confidence: 99%

“…When liver biopsies performed before and after the weight loss caused by the surgery were compared, it was shown that this treatment determines an improvement or stabilization of SS, NASH and fibrosis [ 9 , 10 ]. However, in cirrhosis, the likelihood of regression is reduced and there is an increase in morbidity and mortality after BS [ 8 , 9 , 10 , 11 , 12 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Non-Alcoholic Steatohepatitis (NASH): Risk Factors in Morbidly Obese Patients

Losekann

Weston²,

Mattos

et al. 2015

IJMS

View full text Add to dashboard Cite

The aim was to investigate the prevalence of non-alcoholic steatohepatitis (NASH) and risk factors for hepatic fibrosis in morbidly obese patients submitted to bariatric surgery. This retrospective study recruited all patients submitted to bariatric surgery from January 2007 to December 2012 at a reference attendance center of Southern Brazil. Clinical and biochemical data were studied as a function of the histological findings of liver biopsies done during the surgery. Steatosis was present in 226 (90.4%) and NASH in 176 (70.4%) cases. The diagnosis of cirrhosis was established in four cases (1.6%) and fibrosis in 108 (43.2%). Risk factors associated with NASH at multivariate analysis were alanine aminotransferase (ALT) >1.5 times the upper limit of normal (ULN); glucose ≥ 126 mg/dL and triglycerides ≥ 150 mg/dL. All patients with ALT ≥1.5 times the ULN had NASH. When the presence of fibrosis was analyzed, ALT > 1.5 times the ULN and triglycerides ≥ 150 mg/dL were risk factors, furthermore, there was an increase of 1% in the prevalence of fibrosis for each year of age increase. Not only steatosis, but NASH is a frequent finding in MO patients. In the present study, ALT ≥ 1.5 times the ULN identifies all patients with NASH, this finding needs to be further validated in other studies. Moreover, the presence of fibrosis was associated with ALT, triglycerides and age, identifying a subset of patients with more severe disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Non-Alcoholic Steatohepatitis (NASH): Risk Factors in Morbidly Obese Patients

Losekann

Weston²,

Mattos

et al. 2015

IJMS

View full text Add to dashboard Cite

show abstract

“…46 The FLI has since been utilised by several groups in population studies of NAFLD. [47][48][49] Ultrasound (USS) is a commonly used test in patients with suspected NAFLD, with steatosis typically appearing as a hyperechogenic liver. A recent study examined the accuracy of USS in 235 patients with suspected liver disease who underwent liver biopsy, and showed a sensitivity of 64% and specificity of 97%, rising to 91% and 93% respectively in patients with at least 30% steatosis.…”

Section: Nafld: Making the Diagnosismentioning

confidence: 99%

Systematic review: the diagnosis and staging of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis

Dowman

Tomlinson

Newsome

2010

Aliment Pharmacol Ther

279

247

View full text Add to dashboard Cite

BackgroundNon-alcoholic fatty liver disease (NAFLD) has become the most prevalent cause of liver disease in Western countries. The development of non-alcoholic steatohepatitis (NASH) and fibrosis identifies an at-risk group with increased risk of cardiovascular and liver-related deaths. The identification and management of this at-risk group remains a clinical challenge.AimTo perform a systematic review of the established and emerging strategies for the diagnosis and staging of NAFLD.MethodsRelevant research and review articles were identified by searching PubMed, MEDLINE and EMBASE.ResultsThere has been a substantial development of non-invasive risk scores, biomarker panels and radiological modalities to identify at-risk patients with NAFLD without recourse to liver biopsy on a routine basis. These modalities and algorithms have improved significantly in their diagnosis and staging of fibrosis and NASH in patients with NAFLD, and will likely impact on the number of patients undergoing liver biopsy.ConclusionsStaging for NAFLD can now be performed by a combination of radiological and laboratory techniques, greatly reducing the requirement for invasive liver biopsy.

show abstract

“…reported that the cirrhosis determinant score (CDS) and the hepatitis C antiviral long‐term treatment against cirrhosis (HALT‐C) model were valuable for the differentiation of cirrhosis induced by NASH and HCV infection 47 . A French group proposed the BAAT score 48 and Fibrotest, 49 which assign one point to each of the following items: BMI, ALT, age, and triglycerides. Angulo et al .…”

Section: Biochemical Markers: Non‐invasive Score Assessmentmentioning

confidence: 99%

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan

Okanoue

Umemura

Yasui

et al. 2011

J of Gastro and Hepatol

View full text Add to dashboard Cite

During the past 20 to 30 years, the frequency of patients presenting with nonalcoholic fatty liver diseases (NAFLD) has increased gradually in Japan in proportion to the increase in the population with life-style related diseases. We describe here the current status of the clinical and basic aspects of research into NAFLD in Japan.The increase in the incidence of life-style-related diseases has resulted in an increase in NAFLD throughout the past 20 to 30 years. The rate of obesity in the population is not high compared to western countries but the incidence of NAFLD is similar to those countries. In 2008 we started a nationwide study of NAFLD which has been supported by the Ministry of Labor and Welfare Japan. In this project, we planned to investigate the epidemiology, genetic backgrounds and biochemical markers, and liver injury in patients with diabetes mellitus (DM) and hepatocellular carcinoma in NASH, and treatment of NASH. Approximately 20 to 25% of DM patients showed NAFLD in which the prevalence of NASH might be more than 30 to 40%. Fortunately, we have been able to obtain very interesting results from our group studies, including single necleotide polymorphisms (SNPs) which will be published in the near future.

show abstract

Nonalcoholic fatty liver disease in severely obese individuals: The influence of bariatric surgery

Cited by 24 publications

References 26 publications

Non-Alcoholic Steatohepatitis (NASH): Risk Factors in Morbidly Obese Patients

Non-Alcoholic Steatohepatitis (NASH): Risk Factors in Morbidly Obese Patients

Systematic review: the diagnosis and staging of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan

Contact Info

Product

Resources

About